Valuation: Penumbra, Inc.

Market Cap 12.84B 11.12B 10.39B 9.5B 17.89B 1,225B 18.17B 122B 47.81B 613B 48.21B 47.16B 2,040B P/E 2026 *
73.9x
P/E 2027 * 53.2x
Enterprise Value 12.39B 10.73B 10.03B 9.17B 17.27B 1,182B 17.54B 118B 46.14B 591B 46.54B 45.52B 1,969B EV / Sales 2026 *
7.77x
EV / Sales 2027 * 6.73x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.41%
1 week+0.92%
Current month+1.49%
1 month+2.48%
3 months+1.16%
6 months-3.83%
Current year+4.85%
1 week 322.23
Extreme 322.23
326.5
1 month 315.69
Extreme 315.69
326.5
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+0.92%+35.55%+31.24% 12.84B
-0.17%-0.42%+20.21%+26.79% 6.87B
+5.64%+9.50%+59.16%+38.76% 6.51B
-0.51%+2.09% - - 5.48B
+1.20%-4.46%-26.80%+39.65% 4.41B
+0.77%-2.17%-21.87%-17.42% 4.08B
+5.61%+12.99%+55.53%-43.62% 2.02B
-4.83%-7.23%-21.14%+133.40% 1.73B
+0.92%+6.50%+68.55%-10.15% 1.71B
+1.13%+3.03%-28.31%-43.47% 1.32B
Average +1.01%+753.18%+15.65%+17.24% 4.7B
Weighted average by Cap. +1.11%+756.49%+22.37%+24.34%

Financials

2026 *2027 *
Net sales 1.6B 1.38B 1.29B 1.18B 2.22B 152B 2.26B 15.14B 5.94B 76.12B 5.99B 5.86B 254B 1.8B 1.56B 1.46B 1.33B 2.51B 172B 2.55B 17.08B 6.7B 85.87B 6.76B 6.61B 286B
Net income 176M 153M 143M 130M 246M 16.83B 250M 1.67B 657M 8.42B 662M 648M 28.04B 242M 210M 196M 179M 338M 23.11B 343M 2.3B 902M 11.56B 910M 890M 38.51B
Net Debt -447M -387M -362M -331M -623M -42.63B -633M -4.24B -1.66B -21.33B -1.68B -1.64B -71.03B -729M -631M -590M -539M -1.02B -69.5B -1.03B -6.91B -2.71B -34.77B -2.74B -2.68B -116B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-10 US$325.98 +0.41% 194,695
26-08-07 US$324.66 -0.06% 239,512
26-08-06 US$324.86 +0.51% 262,161
26-08-05 US$323.21 -0.31% 282,960
26-08-04 US$324.22 +0.37% 363,249
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
325.98USD
Average target price
361.83USD
Spread / Average Target
+11.00%

Quarterly revenue - Rate of surprise